Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ionomycin is a polyether antibiotic and a selective calcium ionophore produced by the bacterium Streptomyces conglobatus. It binds divalent cations with high selectivity for Ca2+ over Mg2+, facilitating the transport of calcium ions across biological membranes. Ionomycin is widely used as a research tool to increase intracellular calcium levels, enabling studies of Ca2+-dependent cellular processes such as signal transduction, apoptosis, and cytokine production. It can induce cell activation and promote apoptosis by activating protein kinase C (PKC) pathways and other downstream signaling cascades[1][5][6]. Ionomycin is not approved for clinical use in humans but is extensively utilized in laboratory research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ionomycin.